Viridian Therapeutics, Inc./DE (VRDN) Operating income 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) annual operating income history from SEC filings — each fiscal year as reported.
-$363.4MFY2025 · since FY2016: -$17.0M → -$363.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$363.4M | -21.5% |
| FY2024 | -$299.0M | -17.5% |
| FY2023 | -$254.4M | -89.5% |
| FY2022 | -$134.3M | -68.5% |
| FY2021 | -$79.7M | +27.8% |
| FY2020 | -$110.4M | -162.9% |
| FY2019 | -$42.0M | -26.9% |
| FY2018 | -$33.1M | -24.7% |
| FY2017 | -$26.5M | -56.2% |
| FY2016 | -$17.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN RevenueVRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating marginVRDN Operating cash flowVRDN Free cash flowVRDN Capital expendituresVRDN Return on equityVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Total liabilitiesVRDN Shareholders’ equityVRDN overview →